Biological Significance of EphB4 Expression in Cancer.

Cancer therapy Drug target receptor EphB4 Ephrin signaling tyrosine kinases receptor

Journal

Current protein & peptide science
ISSN: 1875-5550
Titre abrégé: Curr Protein Pept Sci
Pays: United Arab Emirates
ID NLM: 100960529

Informations de publication

Date de publication:
31 Oct 2023
Historique:
received: 28 06 2023
revised: 03 09 2023
accepted: 15 09 2023
medline: 1 11 2023
pubmed: 1 11 2023
entrez: 1 11 2023
Statut: aheadofprint

Résumé

Eph receptors and their Eph receptor-interacting (ephrin) ligands comprise a vital cell communication system with several functions. In cancer cells, there was evidence of bilateral Eph receptor signaling with both tumor-suppressing and tumor-promoting actions. As a member of the Eph receptor family, EphB4 has been linked to tumor angiogenesis, growth, and metastasis, which makes it a viable and desirable target for drug development in therapeutic applications. Many investigations have been conducted over the last decade to elucidate the structure and function of EphB4 in association with its ligand ephrinB2 for its involvement in tumorigenesis. Although several EphB4-targeting drugs have been investigated, and some selective inhibitors have been evaluated in clinical trials. This article addresses the structure and function of the EphB4 receptor, analyses its possibility as an anticancer therapeutic target, and summarises knowledge of EphB4 kinase inhibitors. To summarise, EphB4 is a difficult but potential treatment option for cancers.

Identifiants

pubmed: 37909437
pii: CPPS-EPUB-135758
doi: 10.2174/0113892037269589231017055642
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Asmat Ullah (A)

Clinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou 310014, Zhejiang, China.

Anam Razzaq (A)

College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.

Chuanzan Zhou (C)

Clinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou 310014, Zhejiang, China.

Najeeb Ullah (N)

Department of Biomedical Engineering, Louisiana Tech University, Ruston, LA, 818 Nelson Ave, 71272, USA.

Somia Shehzadi (S)

University Institute of Medical Laboratory Technology, University of Lahore, 54000, Pakistan.

Tariq Aziz (T)

Westlake University, School of Engineering, Hangzhou, Zhejiang Province, 310024, China.

Mohammad Y Alfaifi (MY)

King Khalid University, Faculty of Science, Biology Department, Abha 9004, Saudi Arabia.

Serag Eldin I Elbehairi (SEI)

King Khalid University, Faculty of Science, Biology Department, Abha 9004, Saudi Arabia.

Haroon Iqbal (H)

Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences Hangzhou, Zhejiang 310022, China.

Classifications MeSH